Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States
C-1101 is a potential first-in-class, disease-modifying, non-opioid therapy designed to address the underlying biology of chronic sciatica BURLINGTON, Mass., July 20, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to...
C-1101 is a potential first-in-class, disease-modifying, non-opioid therapy designed to address the underlying biology of chronic sciatica BURLINGTON, Mass., July 20, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.